BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 27565916)

  • 21. Interstitial lung disease secondary to alectinib after interstitial injury induced by crizotinib.
    Kaira K; Naruse I; Shimizu K; Asao T
    J Cancer Res Ther; 2020; 16(4):919-921. PubMed ID: 32930141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
    Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
    Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapid and dramatic response to alectinib in an anaplastic lymphoma kinase rearranged non-small-cell lung cancer patient who is critically ill.
    Yoshida T; Hida T; Yatabe Y
    Anticancer Drugs; 2016 Jul; 27(6):573-5. PubMed ID: 26938871
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ALK Rearrangement Positive Lung Adenocarcinoma in Pregnancy Treated With Alectinib: A Case Report.
    Gonzalez-Mosquera LF; Rous FA; Rogers A; Smith N; Goyert G; Gadgeel S
    Clin Lung Cancer; 2024 Mar; 25(2):e77-e80. PubMed ID: 38057186
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and effectiveness of alectinib in a real-world surveillance study in patients with ALK-positive non-small-cell lung cancer in Japan.
    Masuda N; Ohe Y; Gemma A; Kusumoto M; Yamada I; Ishii T; Yamamoto N
    Cancer Sci; 2019 Apr; 110(4):1401-1407. PubMed ID: 30776174
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted Therapy With Anaplastic Lymphoma Kinase Inhibitor (Alectinib) in Adolescent Metastatic Non-Small Cell Lung Carcinoma: 18F-NaF PET/CT in Response Evaluation.
    Usmani S; Marafi F; Rasheed R; Al Maraghy M; Al Kandari F
    Clin Nucl Med; 2018 Oct; 43(10):752-754. PubMed ID: 30059431
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of triple gene fusion ALK-LRRN2, LTBP1-ALK, and HIP1-ALK in advanced lung adenocarcinoma and response to alectinib: A case report.
    Ning S; Shi C; Zhang H; Li J
    Medicine (Baltimore); 2021 Dec; 100(51):e27999. PubMed ID: 34941039
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
    Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alectinib for the treatment of ALK-positive stage IV non-small cell lung cancer.
    Wong KM; Noonan S; O'Bryant C; Jimeno A
    Drugs Today (Barc); 2015 Mar; 51(3):161-70. PubMed ID: 25876560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A patient with ALK-positive lung adenocarcinoma who survived alectinib-refractory postoperative recurrence for 4 years by switching to ceritinib.
    Matsumura Y; Inomata S; Yamaguchi H; Mine H; Takagi H; Watanabe M; Ozaki Y; Yamaura T; Fukuhara M; Muto S; Okabe N; Hasegawa T; Shio Y; Suzuki H
    Thorac Cancer; 2021 Aug; 12(15):2225-2228. PubMed ID: 34159737
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dramatic response to alectinib in a patient of ALK-rearranged lung cancer with poor performance status.
    Tanaka H; Taima K; Morimoto T; Nakamura K; Tanaka Y; Itoga M; Takanashi S; Okumura K
    BMC Res Notes; 2016 Mar; 9():173. PubMed ID: 26987388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cutaneous sarcoid-like drug reaction caused by an anaplastic lymphoma kinase inhibitor.
    Gleue CA; Shah K; Wentworth A; Bridges A
    J Cutan Pathol; 2021 Mar; 48(3):425-428. PubMed ID: 33128468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful Treatment with Alectinib for Choroidal Metastasis in Anaplastic Lymphoma Kinase Rearranged Non-small Cell Lung Cancer.
    Funazo T; Morita K; Ikegami N; Konishi C; Nakao S; Ariyasu R; Taki M; Nakagawa K; Hwang MH; Yoshimura C; Wakayama T; Nishizaka Y
    Intern Med; 2017 Sep; 56(17):2317-2320. PubMed ID: 28794371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alectinib for ALK-positive non-small-cell lung cancer.
    Rossi A
    Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1005-13. PubMed ID: 27232673
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alectinib for advanced
    Ly AC; Olin JL; Smith MB
    Am J Health Syst Pharm; 2018 Apr; 75(8):515-522. PubMed ID: 29467147
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression.
    Ou SH; Milliken JC; Azada MC; Miller VA; Ali SM; Klempner SJ
    Lung Cancer; 2016 Jan; 91():70-2. PubMed ID: 26464158
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apatinib reverses alectinib resistance by targeting vascular endothelial growth factor receptor 2 and attenuating the oncogenic signaling pathway in echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene-positive lung cancer cell lines.
    Chen Y; Ma G; Su C; Wu P; Wang H; Song X; Yu Q; Zeng A; Zhou S
    Anticancer Drugs; 2018 Nov; 29(10):935-943. PubMed ID: 30074936
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anaplastic Lymphoma Kinase Mutation (
    Carneiro BA; Pamarthy S; Shah AN; Sagar V; Unno K; Han H; Yang XJ; Costa RB; Nagy RJ; Lanman RB; Kuzel TM; Ross JS; Gay L; Elvin JA; Ali SM; Cristofanilli M; Chae YK; Giles FJ; Abdulkadir SA
    Clin Cancer Res; 2018 Jun; 24(12):2732-2739. PubMed ID: 29559559
    [No Abstract]   [Full Text] [Related]  

  • 39. Successful re-introduction of alectinib after inducing interstitial lung disease in a patient with lung cancer.
    Hwang A; Iskandar A; Dasanu CA
    J Oncol Pharm Pract; 2019 Sep; 25(6):1531-1533. PubMed ID: 30572795
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib.
    Takegawa N; Hayashi H; Iizuka N; Takahama T; Ueda H; Tanaka K; Takeda M; Nakagawa K
    Ann Oncol; 2016 May; 27(5):953-5. PubMed ID: 26811347
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.